METTL18

Across TCGA pan-cancer cohorts, METTL18 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated METTL18 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher METTL18 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated METTL18 expression acts as an unfavorable survival marker, although some lineages such as GBM and UCEC show a favorable association.

GBM, CCRCC, and UCEC are the cancer types where METTL18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.587	0.312	.004	8	view →
CCRCC	DFS	Median	II,III,IV	0.140	0.887	.038	6	view →
UCEC	DFS	Median	All	1.000	0.932	.023	6	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	3	view →
PDAC	DFS	Tertile	III,IV	1.000	0.378	.018	3	view →
LSCC	OS	Median	III,IV	0.545	0.902	.007	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

METTL18–GBM (OS)

Open the GBM breakdown →